^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    DV281 (TLR9 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer

    Published date:
    06/09/2021
    Excerpt:
    DV281 was administered via inhalation in 5 dose cohorts at 1-25 mg; nivolumab 240 mg was administered intravenously every two weeks...Twenty-six advanced patients with NSCLC were enrolled. Baseline PD-L1 expression was present in 16 (61.5%); 21 (80.7%) had received previous anti-PD-1/PD-L1. Thirteen patients (50%) had stable disease, 9 (34.6%) had progressive disease, and 4 (15.4%) were not evaluable.
    DOI:
    10.1158/1078-0432.CCR-21-0263